Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
563-03-013 ISMRM Abstract

NOE MRI for Improved Brain Tumor Infiltration

Primary: Neuro - Tumors
Secondary: Preclinical Animal & in vitro MR - Biomarkers
563-03-013 · Image Classification for Brain Cancer · Wednesday, 13 May, 1:40 PM–2:35 PM · Digital Posters Row D
Keywords: CEST & MT CEST / APT / NOE Tumors Tumor vascular Biomarkers CEST MRI in vivo
Accepted
Blake A Benyard 1, Narayan Datt Soni1, Anshuman Swain1, Nishi Srivastava2, Sunil K Khokhar1, Nadir Yehya2, Yi Fan3, Dushyant Kumar1, RAVI PRAKASH REDDY NANGA1, Michael P Frenneaux4, Mohammad Haris1, Ravinder Reddy1
1Department of Radiology, Center for Advanced Metabolic Imaging in Precision Medicine (CAMIPM), University of Pennsylvania, Philadelphia, United States of America
2Children's Hospital of Philadelphia, Philadelphia, United States of America
3University of Pennsylvania, Philadelphia, United States of America
4Hamad Medical Corporation, Doha, Qatar
Presenting Author: Blake A Benyard

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Akakuru OU, Zhang Z, Iqbal MZ, Zhu C, Zhang Y, Wu A. Chemotherapeutic nanomaterials in tumor boundary delineation: Prospects for effective tumor treatment. Acta Pharm Sin B. 2022;12(6):2640-2657.
2. Matchett KB, Lynam-Lennon N, Watson RW, Brown JAL. Advances in Precision Medicine: Tailoring Individualized Therapies. Cancers (Basel). 2017;9(11):146.
3. Mirnezami R., Nicholson J., Darzi A. Preparing for precision medicine. N. Engl. J. Med. 2012; 366:489–491.
4. Ciardiello F., Arnold D., Casali P.G., Cervantes A., Douillard J.Y., Eggermont A., Eniu A., McGregor K., Peters S., Piccart M., et al. Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: A position paper by the European Society for Medical Oncology (ESMO) Ann. Oncol. 2014; 25:1673–1678.
5. Molinaro AM, Hervey-Jumper S, Morshed RA, et al. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma [published correction appears in JAMA Oncol. 2020 Mar 1;6(3):444.
6. Liu L, Liao C, Ge S, et al. Aggressive resection of non-contrast-enhanced tumor provides varying benefits to glioblastoma, IDH-wildtype patients based on different clinical characteristics. Cancer Lett. 2025;612:217471.
7. Zu Z, Lin EC, Louie EA, et al. Relayed nuclear Overhauser enhancement sensitivity to membrane Cho phospholipids. Magn Reson Med. 2020;84(4):1961-1976.
8. Paech, D., Burth, S., Windschuh, J., et al. Nuclear Overhauser Enhancement imaging of glioblastoma at 7 Tesla: region specific correlation with apparent diffusion coefficient and histology. PloS one. 2015, 10(3):e0121220.
9. Zaiss M, Windschuh J, Paech D, et al. Relaxation-compensated CEST- MRI of the human brain at 7 T: Unbiased insight into NOE and amide signal changes in human glioblastoma. Neuroimage. 2015, 112:180-188.
10. Benyard B, Nanga RPR, Wilson NE, et al. In vivo reproducibility of 3D relayed NOE in the healthy human brain at 7 T. Magn Reson Med. 2023;89(6):2295-2304

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/563-03-013